Wang J, Wei SR, Ding T, Zhang LP, Weng ZH, Cheng M, Zhou Y, Zhang M, Liu FJ, Yan BB, Wang DF, Sun MW, Cheng WX. Continuous renal replacement therapy with oXiris® in patients with hematologically malignant septic shock: A retrospective study. World J Clin Cases 2023; 11(26): 6073-6082 [PMID: 37731565 DOI: 10.12998/wjcc.v11.i26.6073]
Corresponding Author of This Article
Wei-Xin Cheng, MD, Doctor, Emergency Department, Peking University International Hospital, No. 1 Life Park Road, Life Science Park of Zhong Guancun, Changping District, Beijing 102206, China. 18911652172@163.com
Research Domain of This Article
Hematology
Article-Type of This Article
Retrospective Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Clin Cases. Sep 16, 2023; 11(26): 6073-6082 Published online Sep 16, 2023. doi: 10.12998/wjcc.v11.i26.6073
Continuous renal replacement therapy with oXiris® in patients with hematologically malignant septic shock: A retrospective study
Juan Wang, Shu-Run Wei, Tong Ding, Li-Ping Zhang, Zhi-Hua Weng, Ming Cheng, Yang Zhou, Meng Zhang, Fang-Jun Liu, Bei-Bei Yan, Dan-Feng Wang, Ming-Wen Sun, Wei-Xin Cheng
Juan Wang, Shu-Run Wei, Tong Ding, Li-Ping Zhang, Zhi-Hua Weng, Ming Cheng, Yang Zhou, Meng Zhang, Fang-Jun Liu, Bei-Bei Yan, Dan-Feng Wang, Ming-Wen Sun, Intensive Care Unit, Hebei Yanda Hospital, Langfang 065201, Hebei Province, China
Wei-Xin Cheng, Department of Emergency, Peking University International Hospital, Beijing 102206, China
Author contributions: Wang J and Cheng WX were responsible for research design, statistics and paper writing; Wei SR, Ding T, Zhang LP, Weng ZH, Cheng M, Zhou Y, Zhang M, Liu FJ, Yan BB, Wang DF, and Sun MW were responsible for the collation of data; all authors proofed the manuscript.
Supported byHebei Health Science and Education Project, No. 20200852.
Institutional review board statement: This study was approved by the hospital’s ethics committee.
Informed consent statement: Patients were not required to provide informed consent for the study because the analysis used anonymous clinical data that were obtained after each patient or their representative family members agreed to the treatment by written consent.
Conflict-of-interest statement: The authors declare no conflicts of interest.
Data sharing statement: Some or all data, models, or codes generated or used during the study are available from the corresponding author upon request.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Wei-Xin Cheng, MD, Doctor, Emergency Department, Peking University International Hospital, No. 1 Life Park Road, Life Science Park of Zhong Guancun, Changping District, Beijing 102206, China. 18911652172@163.com
Received: April 21, 2023 Peer-review started: April 21, 2023 First decision: June 14, 2023 Revised: July 4, 2023 Accepted: July 14, 2023 Article in press: July 14, 2023 Published online: September 16, 2023 Processing time: 139 Days and 23.9 Hours
ARTICLE HIGHLIGHTS
Research background
The mortality rate from septic shock in patients with hematological malignancies (HMs) remains significantly higher than that in patients without HMs.
Research motivation
Continuous renal replacement therapy (CRRT) with oXiris® might shorten the time from resuscitation to fluid negative balance. It may also improve hemodynamic parameters and decrease the blood levels of inflammatory mediators.
Research objectives
This study aimed to explore the effects of CRRT and oXiris® in shortening the resuscitation time as well as a modifier for the host response by reducing levels of inflammation mediators.
Research methods
Patients with HMs who were diagnosed with septic shock and underwent CRRT were divided into two groups based on the hemofilter used. The days with negative balance and total fluid balance after 7 d of CRRT were compared between the groups. The heart rate, norepinephrine dose, Sequential Organ Failure Assessment (SOFA) score, and blood lactic acid levels at different time points in the two groups were also compared.
Research results
The average total fluid balance after 7 d of CRRT in the oXiris® group was significantly lower than that of patients in the M150 hemofilter group, and the SOFA scores of patients after CRRT with oXiris® therapy were significantly lower than those before treatment on day 1 (d1), d3 and d7 after CRRT; these parameters were also significantly lower than those of the control group on d7. Lactate levels after CRRT with oXiris® therapy were significantly lower than those before treatment on d3 and d7 after CRRT. In the oXiris® group, procalcitonin levels decreased on d7, and interleukin-6 and tumor necrosis factor- levels reduced significantly on both d3 and d7 after oXiris® treatment.
Research conclusions
CRRT with oXiris® hemofilter might improve the hemodynamic parameters and play a role in shortening the resuscitation period, thus decreasing the total fluid balance in the resuscitation phase.
Research perspectives
CRRT with an oXiris® hemofilter may be used as a host response modulation method in patients with septic shock and HM. This may improve hemodynamic parameters by reducing the levels of inflammatory mediators.
